APA (7th ed.) Citation

Y, N., I, H., H, A., M, U., S, N., Y, N., . . . A, K. (2025). Real-world clinical experience of reduced-dose initiation of lenvatinib in Japanese patients with radioiodine-refractory differentiated thyroid cancer. Endocrine journal, 72(12), 1327. https://doi.org/10.1507/endocrj.EJ25-0251

Chicago Style (17th ed.) Citation

Y, Nakashima, et al. "Real-world Clinical Experience of Reduced-dose Initiation of Lenvatinib in Japanese Patients with Radioiodine-refractory Differentiated Thyroid Cancer." Endocrine Journal 72, no. 12 (2025): 1327. https://doi.org/10.1507/endocrj.EJ25-0251.

MLA (9th ed.) Citation

Y, Nakashima, et al. "Real-world Clinical Experience of Reduced-dose Initiation of Lenvatinib in Japanese Patients with Radioiodine-refractory Differentiated Thyroid Cancer." Endocrine Journal, vol. 72, no. 12, 2025, p. 1327, https://doi.org/10.1507/endocrj.EJ25-0251.